Our Work

Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.

dQ&A is announcing the availability of new data collected this quarter from ten thousand people with diabetes in the USA, Canada and seven EU countries.

Our European study explores Time in Range in diabetes, comparing outcomes and differences across six countries.